Gilead, As­traZeneca/Dai­ichi Sankyo of­fer first look at TROP2 AD­Cs in first-line lung can­cer as ri­val­ry heats up 

Pre­lim­i­nary mid-stage da­ta from two ri­val TROP2-tar­get­ing AD­Cs ad­vanced by As­traZeneca/Dai­ichi Sankyo and Gilead, com­bined with im­mune check­point in­hibitors, have pro­vid­ed a first glance at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER